

Online Supplementary Material

Kruse RL, Mehr DR, van der Steen JT, et al. Antibiotic treatment and survival of nursing home patients with lower respiratory infection: a cross-national analysis. *Ann Fam Med*. 2005;3:422.

<http://www.annfammed.org/cgi/content/full/3/5/422/DC1>

**Supplemental Table 1. Mortality at 1 and 3 Months by Nation, Initial Antibiotic Treatment, and Mortality Risk Predicted by Logistic Regression Models**

Antibiotic Treatment	Predicted Probability of Mortality					
	N Died/N (% Mortality)					
	0.0-0.049	0.05-0.099	0.1-0.149	0.15-0.249	0.25-0.399	≥0.40
<b>1-month mortality, US residents</b>						
Oral amoxicillin	0/19 (0.0)	0/27 (0.0)	2/15 (13.3)	3/14 (21.4)	0/9 (0.0)	3/7 (42.9)
Oral amoxicillin/clavulanate	1/12 (8.3)	0/2 (0.0)	0/6 (0.0)	0/6 (0.0)	0/5 (0.0)	1/1 (100.0)
Oral doxycycline, tetracycline, TMP-SMX, or macrolide	3/62 (4.8)	1/64 (1.6)	2/34 (5.9)	5/36 (13.9)	10/22 (45.4)	2/6 (33.3)
Flouroquinolone with or without another agent	0/14 (0.0)	4/25 (16.0)	4/23 (17.4)	0/16 (0.0)	6/21 (28.6)	4/8 (50.0)
First-generation or oral second-generation cephalosporin	0/22 (0.0)	3/25 (12.0)	2/16 (12.5)	4/19 (21.0)	3/7 (42.9)	1/2 (50.0)
Third-generation or parenteral second-generation cephalosporin	1/15 (6.7)	6/30 (20.0)	2/23 (8.7)	7/34 (20.6)	6/31 (19.4)	6/14 (42.9)
All other regimens	0/10 (0.0)	4/20 (20.0)	4/16 (25.0)	9/28 (32.1)	6/23 (26.1)	7/17 (41.2)
Total United States	5/154 (3.2)	18/193 (9.3)	16/133 (12.0)	28/153 (18.3)	31/118 (26.3)	24/55 (43.6)
		<b>0.0-0.099</b>	<b>0.1-0.149</b>	<b>0.15-0.249</b>	<b>0.25-0.399</b>	<b>≥0.40</b>
<b>1-month mortality, Dutch residents</b>						
Oral amoxicillin*		2/48 (4.2)	5/29 (17.2)	7/44 (15.9)	17/55 (30.9)	17/31 (54.8)
Oral amoxicillin/clavulanate		0/22 (0.0)	1/11 (9.1)	3/25 (12.0)	4/10 (40.0)	13/17 (76.5)
Oral doxycycline, tetracycline, TMP-SMX, or macrolide		1/14 (7.1)	0/7 (0.0)	2/10 (20.0)	10/17 (58.8)	5/8 (62.5)
Intramuscular ampicillin or amoxicillin, followed by oral amoxicillin		0/3 (0.0)	0/3 (0.0)	1/3 (33.3)	6/13 (46.2)	12/24 (50.0)
All other regimens <sup>†</sup>		0/1 (0.0)	1/2 (50.0)	2/2 (100.0)	2/6 (33.3)	4/4 (100.0)
Total Dutch		3/88 (3.4)	7/52 (13.5)	15/84 (15.9)	39/101 (38.6)	51/84 (60.7)

*Continued*

## Online Supplementary Data

<http://www.annfammed.org/cgi/content/full/3/5/422/DC1>

Antibiotic Treatment	0.0-0.049	0.05-0.099	0.1-0.149	0.15-0.249	0.25-0.399	≥0.40
<b>3-month mortality, US residents</b>						
Oral amoxicillin	0/4 (0.0)	1/15 (6.7)	2/14 (14.3)	3/28 (10.7)	4/16 (25.0)	6/14 (42.9)
Oral amoxicillin/clavulanate	1/2 (50.0)	1/7 (14.3)	0/3 (0.0)	1/7 (14.3)	1/12 (8.3)	1/1 (100.0)
Oral doxycycline, tetracycline, TMP-SMX, or macrolide	0/7 (0.0)	1/46 (2.2)	6/42 (14.3)	8/52 (15.4)	9/53 (17.0)	17/24 (70.8)
Fluoroquinolone with or without another agent	0/6 (0.0)	0/11 (0.0)	4/17 (23.5)	7/24 (29.2)	7/35 (20.0)	7/14 (50.0)
First-generation or oral second-generation cephalosporin	0/9 (0.0)	0/10 (0.0)	1/11 (9.1)	7/29 (24.1)	5/21 (23.8)	7/11 (63.6)
Third-generation or parenteral second-generation cephalosporin	0/4 (0.0)	2/12 (16.7)	2/16 (12.5)	9/29 (31.0)	16/44 (36.4)	19/42 (45.2)
All other regimens	0/0	1/9 (11.1)	4/13 (30.8)	4/20 (20.0)	19/39 (48.7)	17/33 (51.5)
Total United States	1/32 (3.1)	6/110 (5.4)	19/116 (16.4)	39/189 (20.6)	61/220 (27.7)	74/139 (53.2)
		<b>0.0-0.099</b>	<b>0.1-0.149</b>	<b>0.15-0.249</b>	<b>0.25-0.399</b>	<b>≥0.40</b>
<b>3-month mortality, Dutch residents</b>						
Oral amoxicillin*		1/11 (9.1)	2/25 (8.0)	8/41 (19.5)	20/60 (33.3)	31/68 (45.6)
Oral amoxicillin/clavulanate		0/5 (0.0)	1/10 (10.0)	4/22 (18.2)	6/20 (30.0)	17/24 (70.8)
Oral doxycycline, tetracycline, TMP-SMX, or macrolide		1/4 (25.0)	2/10 (20.0)	2/5 (40.0)	6/16 (37.5)	14/21 (66.7)
Intramuscular ampicillin or amoxicillin, followed by oral amoxicillin		0/1 (0.0)	0/2 (0.0)	0/3 (0.0)	3/7 (42.9)	18/33 (54.6)
All other regimens†		0/1 (0.0)	0.0	2/2 (100.0)	5/5 (100.0)	4/7 (57.1)
Total Dutch		2/22 (9.1)	5/47 (10.6)	16/73 (21.9)	40/108 (37.0)	84/153 (54.9)
TMP-SMX = trimethoprim-sulfamethoxazole. * Includes 2 Dutch residents who received oral penicillin. † Includes fluoroquinolones and cephalosporins as listed for the US residents. The categories were combined because so few Dutch residents received these regimens.						